{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:58:23Z","timestamp":1783594703093,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bruton\u2019s tyrosine kinase (Btk) is an enzyme expressed in leukocytes other than T lymphocytes and plasma cells and involved in B-cell receptor- and Fc\u03b3 receptor (Fc\u03b3R)-mediated signal transduction. Btk inhibitors potentially suppress autoantibody production due to the expected inhibitory ability of B lymphocyte differentiation into antibody-producing plasma cells and reduce Fc\u03b3R-mediated neutrophil activation, including the release of neutrophil extracellular traps (NETs). Microscopic polyangiitis (MPA) is a systemic small-vessel vasculitis characterized by the pathogenic autoantibody, antineutrophil cytoplasmic antibody (ANCA) that reacts with myeloperoxidase (MPO). MPO and MPO-ANCA immune complex (IC)-induced Fc\u03b3R-mediated NETs are critically involved in MPA pathogenesis. This study aimed to demonstrate the therapeutic efficacy of the Btk inhibitor tirabrutinib on MPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Various doses of tirabrutinib or vehicle were orally administered to Sprague\u2013Dawley rats daily. Four weeks later, the number of peripheral B lymphocytes was counted, and Btk phosphorylation in B lymphocytes was evaluated by flow cytometry. Human peripheral blood neutrophils were stimulated by MPO and anti-MPO antibody ICs (MPO and anti-MPO-ICs), and Btk and its downstream Vav phosphorylation were assessed by western blotting. The effects of tirabrutinib on MPO and anti-MPO-IC-induced NET formation were examined in vitro. Wistar Kyoto rats were immunized with human MPO to induce experimental MPA and given drug-free or tirabrutinib-containing feed (0.0037% or 0.012%) from day 0 or 28. All rats were euthanized on day 42 for serological and histological evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tirabrutinib inhibited Btk phosphorylation without decreasing B lymphocytes in vivo. Neutrophil Btk and Vav were phosphorylated when stimulated with MPO and anti-MPO-ICs. Tirabrutinib suppressed MPO and anti-MPO-IC-induced NET formation in vitro and ameliorated experimental MPA in a dose-dependent manner in vivo. Although MPO-ANCA production was not affected, NET-forming neutrophils in the blood were significantly reduced by tirabrutinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Btk inhibitor tirabrutinib suppressed MPO and anti-MPO-IC-induced NET formation in vitro and ameliorated experimental MPA by reducing NET-forming neutrophils but not decreasing MPO-ANCA titer in vivo. This study suggests that Btk is a possible therapeutic target in MPA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-023-03201-9","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T03:01:53Z","timestamp":1699239713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bruton\u2019s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis"],"prefix":"10.1186","volume":"25","author":[{"given":"Issei","family":"Nakade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ariza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Fujigaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suishin","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hodaka","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Nishibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utano","family":"Tomaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"3201_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57.","journal-title":"Mol Cancer"},{"key":"3201_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.36648\/2248-9215.9.1.79","volume":"9","author":"Y Ariza","year":"2019","unstructured":"Ariza Y, Murata M, Ueda Y, et al. Bruton\u2019s tyrosine kinase (Btk) inhibitor tirabrutinib prevents the development of murine lupus. Eur J Exp Biol. 2019;9:2.","journal-title":"Eur J Exp Biol"},{"key":"3201_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/imm.13423","volume":"165","author":"A Singhal","year":"2022","unstructured":"Singhal A, Kumar S. Neutrophil and remnant clearance in immunity and inflammation. Immunology. 2022;165:22\u201343.","journal-title":"Immunology"},{"key":"3201_CR4","doi-asserted-by":"publisher","first-page":"L52","DOI":"10.1152\/ajplung.00047.2018","volume":"315","author":"JM Florence","year":"2018","unstructured":"Florence JM, Krupa A, Booshehri LM, et al. Inhibiting Bruton\u2019s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018;315:L52\u20138.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3201_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/vaccines9060597","volume":"9","author":"ST George","year":"2021","unstructured":"George ST, Lai J, Ma J, et al. Neutrophils and influenza: a thin line between helpful and harmful. Vaccines (Basel). 2021;9:597.","journal-title":"Vaccines (Basel)"},{"key":"3201_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","volume":"15","author":"D Nakazawa","year":"2019","unstructured":"Nakazawa D, Masuda S, Tomaru U, et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol. 2019;15:91\u2013101.","journal-title":"Nat Rev Rheumatol"},{"key":"3201_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","volume":"81","author":"R Suppiah","year":"2022","unstructured":"Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81:321\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3201_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1365-2249.1994.tb06137.x","volume":"98","author":"AH Mulder","year":"1994","unstructured":"Mulder AH, Heeringa P, Brouwer E, et al. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc\u03b3 RII-dependent process. Clin Exp Immunol. 1994;98:270\u20138.","journal-title":"Clin Exp Immunol"},{"key":"3201_CR9","doi-asserted-by":"publisher","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ard-2022-223764.","DOI":"10.1136\/ard-2022-223764"},{"key":"3201_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599\u2013609.","journal-title":"N Engl J Med"},{"key":"3201_CR11","doi-asserted-by":"publisher","first-page":"18204","DOI":"10.1038\/srep18204","volume":"5","author":"CY Chen","year":"2015","unstructured":"Chen CY, Leu YL, Fang Y, et al. Anti-inflammatory effects of Perilla frutescens in activated human neutrophils through two independent pathways: Src family kinases and Calcium. Sci Rep. 2015;5:18204.","journal-title":"Sci Rep"},{"key":"3201_CR12","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1038\/s41467-018-06263-5","volume":"9","author":"E Neubert","year":"2018","unstructured":"Neubert E, Meyer D, Rocca F, et al. Chromatin swelling drives neutrophil extracellular trap release. Nat Commun. 2018;9:3767.","journal-title":"Nat Commun"},{"key":"3201_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13075-022-02974-9","volume":"24","author":"M Yoshinari","year":"2022","unstructured":"Yoshinari M, Nishibata Y, Masuda S, et al. Low disease activity of microscopic polyangiitis in patients with anti-myosin light chain 6 antibody that disrupts actin rearrangement necessary for neutrophil extracellular trap formation. Arthritis Res Ther. 2022;24:274.","journal-title":"Arthritis Res Ther"},{"key":"3201_CR14","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2353\/ajpath.2009.080458","volume":"174","author":"MA Little","year":"2009","unstructured":"Little MA, Smyth L, Salama AD, et al. Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol. 2009;174:1212\u201320.","journal-title":"Am J Pathol"},{"key":"3201_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/cyto.a.23169","volume":"91","author":"S Masuda","year":"2017","unstructured":"Masuda S, Shimizu S, Matsuo J, et al. Measurement of NET formation in vitro and in vivo by flow cytometry. Cytometry A. 2017;91:822\u20139.","journal-title":"Cytometry A"},{"key":"3201_CR16","doi-asserted-by":"publisher","first-page":"e0282166","DOI":"10.1371\/journal.pone.0282166","volume":"18","author":"R Kozaki","year":"2023","unstructured":"Kozaki R, Yasuhiro T, Kato H, et al. Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton\u2019s tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. PLoS One. 2023;18:e0282166.","journal-title":"PLoS One"},{"key":"3201_CR17","doi-asserted-by":"publisher","first-page":"102390","DOI":"10.1016\/j.jaut.2019.102390","volume":"108","author":"K Watanabe-Kusunoki","year":"2020","unstructured":"Watanabe-Kusunoki K, Nakazawa D, Kusunoki Y, et al. Recombinant thrombomodulin ameliorates autoimmune vasculitis via immune response regulation and tissue injury protection. J Autoimmun. 2020;108:102390.","journal-title":"J Autoimmun"},{"key":"3201_CR18","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","volume":"202","author":"P Haselmayer","year":"2019","unstructured":"Haselmayer P, Camps M, Liu-Bujalski L, et al. Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models. J Immunol. 2019;202:2888\u2013906.","journal-title":"J Immunol"},{"key":"3201_CR19","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1073\/pnas.90.13.6305","volume":"90","author":"F Hamada","year":"1993","unstructured":"Hamada F, Aoki M, Akiyama T, et al. Association of immunoglobulin G Fc receptor II with Src-like protein-tyrosine kinase Fgr in neutrophils. Proc Natl Acad Sci U S A. 1993;90:6305\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3201_CR20","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1111\/bph.15597","volume":"178","author":"TI Kao","year":"2021","unstructured":"Kao TI, Chen PJ, Wang YH, et al. Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity. Br J Pharmacol. 2021;178:4069\u201384.","journal-title":"Br J Pharmacol"},{"key":"3201_CR21","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/j.lpm.2015.02.019","volume":"44","author":"O Flossmann","year":"2015","unstructured":"Flossmann O. Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis. Presse Med. 2015;44:e251\u20137.","journal-title":"Presse Med"},{"key":"3201_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4049\/immunohorizons.2200012","volume":"6","author":"PM Lelliott","year":"2022","unstructured":"Lelliott PM, Nishide M, Pavillon N, et al. Cellular adhesion is a controlling factor in neutrophil extracellular trap formation induced by anti-neutrophil cytoplasmic antibodies. Immunohorizons. 2022;6:170\u201383.","journal-title":"Immunohorizons"},{"key":"3201_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1681\/ASN.V83386","volume":"8","author":"R Kettritz","year":"1997","unstructured":"Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol. 1997;8:386\u201394.","journal-title":"J Am Soc Nephrol"},{"key":"3201_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/art.42321","volume":"75","author":"M Prendecki","year":"2023","unstructured":"Prendecki M, Gulati K, Pisacano N, et al. Syk activation in circulating and tissue innate immune cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2023;75:84\u201397.","journal-title":"Arthritis Rheumatol"},{"key":"3201_CR25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1172\/JCI0215918","volume":"110","author":"H Xiao","year":"2002","unstructured":"Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955\u201363.","journal-title":"J Clin Invest"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03201-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03201-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03201-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T03:03:56Z","timestamp":1699239836000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03201-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3201"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03201-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3297700\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"26 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments using human materials were permitted by the Ethical Committee of the Faculty of Health Sciences, Hokkaido University (permission no. 20\u201340) and performed in accordance with the Declaration of Helsinki. After obtaining written informed consent, peripheral blood (10\u00a0ml) was drawn from healthy volunteers. Experiments using rats were permitted by the Animal Experiments Committee of Hokkaido University (permission no. 20\u20130032) and performed in accordance with the Guidelines for the Care and Use of Laboratory Animals at Hokkaido University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y.A., S.H., and H.F. are employees of Ono Pharmaceutical Corp. Ltd. Y.N., S.M., and A.I. were given research funding by Ono Pharmaceutical Corp. Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}